Evidence map›Paper›PMID 35416486›Full record

ArticleApplied microbiology and biotechnology2022

Characterization of a bioactive meroterpenoid isolated from the marine-derived fungus Talaromyces sp.

Xuan Hong, Xiaoqing Guan, Qiliang Lai, Dehua Yu, Zhongwei Chen, Xiaoteng Fu, Beibei Zhang, Changkun Chen, Zongze Shao, Jinmei Xia and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xuan Hong *Fujian Universities and Colleges Engineering Research Center of Marine Biopharmaceutical Resources, Xiamen Medical College, 361023, Xiamen, China.
Xiaoqing Guan *The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Qiliang Lai *Key Laboratory of Marine Biogenetic Resources, Third Institute of Oceanography, Ministry of Natural Resources, 361005, Xiamen, China.
Dehua YuThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Zhongwei ChenFujian Universities and Colleges Engineering Research Center of Marine Biopharmaceutical Resources, Xiamen Medical College, 361023, Xiamen, China.
Xiaoteng FuKey Laboratory of Marine Biogenetic Resources, Third Institute of Oceanography, Ministry of Natural Resources, 361005, Xiamen, China.
Beibei ZhangKey Laboratory of Marine Biogenetic Resources, Third Institute of Oceanography, Ministry of Natural Resources, 361005, Xiamen, China.
Changkun ChenFujian Universities and Colleges Engineering Research Center of Marine Biopharmaceutical Resources, Xiamen Medical College, 361023, Xiamen, China.
Zongze ShaoKey Laboratory of Marine Biogenetic Resources, Third Institute of Oceanography, Ministry of Natural Resources, 361005, Xiamen, China.
Jinmei XiaKey Laboratory of Marine Biogenetic Resources, Third Institute of Oceanography, Ministry of Natural Resources, 361005, Xiamen, China. xiajinmei@tio.org.cn.
Jiang-Jiang QinThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China. jqin@ucas.ac.cn.
Weiyi WangKey Laboratory of Marine Biogenetic Resources, Third Institute of Oceanography, Ministry of Natural Resources, 361005, Xiamen, China. wywang@tio.org.cn.ORCID http://orcid.org/0000-0003-3163-9491

Funding

COMRA program DY135-B2-01COMRA program DY135-B2-05Deep Sea Habitats Discovery Project DY-XZ-04National Natural Science Foundation of China 41906104National Natural Science Foundation of China 81903842Natural Science Foundation of Fujian Province 2021J01509Natural Science Foundation of Zhejiang Province LR21H280001Natural Science Foundation of Zhejiang Province Q22H287247Research project on education and teaching reform in undergraduate colleges and universities of Fujian Province FBJG20190201Scientific Research Foundation of Third Institute of Oceanography MNR 2019021Scientific Research Foundation of Third Institute of Oceanography SOA 2018021
6 · The paper itself

Abstract

A new meroterpenoid, taladrimanin A (1), was isolated from a marine-derived fungus Talaromyces sp. HM6-1-1, together with eleven biogenetically related compounds (2-12). A plausible biosynthetic pathway for the meroterpenoids (1-4) was proposed. The planar structure of 1 was assigned by HRESIMS and NMR. Its relative configuration was established by quantum chemical NMR calculation of two possible isomers and analyzed by DP4 + method. Finally, X-ray diffraction unambiguously confirmed the relative configuration and revealed the absolute configuration of compound 1. 2-12 were assigned by comparing their NMR data with those reported in the literature. 1 was the first drimane-type meroterpenoid with a C10 polyketide unit bearing an 8R-configuration. In the bioactive assay, 1 exhibited antitumor activity against gastric cancer cells MGC803 and MKN28; it also inhibited the colony formation and induced apoptosis in MGC803 cells both in a concentration-dependent manner. Additionally, 1 displayed selective antibacterial activity against Staphylococcus aureus 6538P, and low activities towards strains of Vibrio parahaemolyticus and Escherichia coli in this study. KEY POINTS: • Twelve compounds were obtained from Talaromyces sp., including four meroterpenoids, one of which was new. • The new compound taladrimanin A (1) inhibits the growth of gastric cancer cells MGC803 and MKN28 as well as the pathogenic bacteria Staphylococcus aureus 6538P. • The biosynthetic pathway of the meroterpenoids was proposed.

Indexed as

Stomach NeoplasmsTalaromycesAnti-Bacterial AgentsEscherichia coliHumansMolecular StructureStaphylococcus aureusAnti-Bacterial AgentsAntibacterialCytotoxicMeroterpenoidTalaromyces

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.